Appellant's Claim for Nil Rate of Countervailing Duty Dismissed for Non-Compliance

The Tribunal dismissed the appellant's claim for a nil rate of Countervailing Duty (CVD) as they failed to demonstrate compliance with the specified standards, leading to the rejection of their exemption claim. The appeal was dismissed, upholding the decision of the lower authorities.

---

---

ISSUES PRESENTED AND CONSIDERED

1. Whether the importer was entitled to nil countervailing duty (CVD) under the specified notification entry for "bulk drugs specified in List 1" where the imported item is Hydrocortisone listed in List 1 but no conformity to pharmacopoeial or other standards was demonstrated prior to clearance?

2. Whether the claimed denial of exemption constituted a clerical error correctable under Section 17(2) or by exercise of powers under Sections 149/154 of the Customs Act after goods were cleared Out of Charge (OOC)?

ISSUE-WISE DETAILED ANALYSIS

Issue 1 - Entitlement to nil CVD under the notification for bulk drugs in List 1

Legal framework: The entry conferring nil CVD applies to "bulk drugs specified in List 1" as described in the notification; an explanation appended to the entry defines "bulk drug" to mean pharmaceutical/chemical/biological/plant products (including salts, esters, stereo-isomers and derivatives) conforming to pharmacopoeial or other standards specified in the Second Schedule to the Drugs and Cosmetics Act, 1940, and used as such or as ingredient in any formulation.

Precedent Treatment: The Court relied on the textual interplay between the entry and its explanation; no prior authority was cited or overruled in the judgment.

Interpretation and reasoning: The description in Column (3) must be read together with the explanation; the explanation materially narrows eligibility by requiring conformity to the pharmacopoeial or other standards in the Second Schedule to the Drugs and Cosmetics Act, 1940. It is incumbent on the importer to demonstrate that imported goods conform to those standards to claim nil CVD. Mere presence of the drug name (Hydrocortisone) in List 1 is insufficient without evidence of conformity. Post-clearance assertions do not substitute for contemporaneous demonstration, especially where goods have been released from Customs control and are not available for testing.

Ratio vs. Obiter: Ratio - The explanation to a tariff/notification entry is integral to the description and controls eligibility for concession; importers must demonstrate conformity to specified pharmacopoeial standards to claim the exemption. Obiter - None significant beyond application of the ratio to factual circumstances.

Conclusions: The claim for nil CVD was properly rejected because the importer failed to demonstrate conformity with the pharmacopoeial or other standards required by the notification's explanation; the authorities below correctly denied the exemption.

Issue 2 - Whether the denial of exemption was a correctable clerical error under Section 17(2) or Section 149/154 after OOC

Legal framework: Section 17(2) (and related provisions) permit rectification of certain errors in assessment; Sections 149/154 (referenced) empower correction of clerical/arithmetical mistakes and review of orders in specific circumstances. Corrective powers are constrained by the factual and legal matrix governing assessments and by the requirement that eligibility conditions for concessions be demonstrably met.

Precedent Treatment: The Court applied statutory principles of correction and rectification to the facts; no change in law or precedent treatment was invoked.

Interpretation and reasoning: The appellant characterized the failure to claim the notification benefit as a clerical error. The Court held that the omission was not a mere clerical slip because entitlement depends on a substantive factual/legal requirement (conformity to pharmacopoeial/Second Schedule standards) which was neither demonstrated nor ascertainable after release. Correction under Section 17(2) or Sections 149/154 cannot be used to grant a substantive concession where the statutory eligibility condition was not fulfilled or evidenced at the time of clearance and where the goods are no longer under Customs control for testing or verification. The lower authorities could not properly exercise rectification powers to confer a concession when the foundational compliance requirement was unmet.

Ratio vs. Obiter: Ratio - Rectification powers cannot be used to confer a statutorily conditioned exemption where the importer failed to demonstrate conformity with prescribed standards and goods were released prior to any such demonstration or testing. Obiter - Observations on the preferred exercise of powers by the original authority (that Section 17(2) could correct clerical errors where applicable) are peripheral and do not alter the core holding.

Conclusions: The request for reassessment or correction to grant the notification benefit was rightly refused. The omission was not a correctable clerical error in substance because the statutory precondition (demonstrable conformity to specified pharmacopoeial standards) was not met or demonstrable once goods were OOC; hence rectification to allow nil CVD was not permissible.

Cross-reference

The resolution of Issue 2 follows from, and is dependent upon, Issue 1: because entitlement to the notification depended on demonstrable conformity to standards (Issue 1), the failure to show such conformity rendered the asserted clerical error substantive rather than a clerical/innocuous omission correctable under the cited statutory provisions (Issue 2).

Final Disposition (legal conclusion)

The appeal is dismissed: the authorities correctly denied nil CVD where the importer failed to establish conformity to the pharmacopoeial/Second Schedule standards required by the notification's explanation, and the omission could not be remedied as a clerical error after the goods were released from Customs control.

---